Search research articles
Contact Us
Filters
Showing results (681-690 of 694) with videos related to
Page
of 70
Sort By:
Journal of Medicinal Chemistry
|
August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)
Richard A Ward, Mark J Anderton, Susan Ashton, et al.
Cancer Research
|
March 21, 2020
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance <i>EGFR</i> Mutations
Jacqueline H Starrett, Alexis A Guernet, Maria Emanuela Cuomo, et al.
Genome Research
|
June 5, 2019
Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging
Aaron R Jeffries, Reza Maroofian, Claire G Salter, et al.
The Journal of Clinical Investigation
|
April 2, 2013
SLITRK6 mutations cause myopia and deafness in humans and mice
Mustafa Tekin, Barry A Chioza, Yoshifumi Matsumoto, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
September 8, 2022
Biallelic DAW1 variants cause a motile ciliopathy characterized by laterality defects and subtle ciliary beating abnormalities
Joseph S Leslie, Rim Hjeij, Asaf Vivante, et al.
Nature Communications
|
January 11, 2018
Guiding of relativistic electron beams in dense matter by laser-driven magnetostatic fields
M Bailly-Grandvaux, J J Santos, C Bellei, et al.
Cancer Discovery
|
June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Journal of Medicinal Chemistry
|
September 7, 2021
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
M Raymond V Finlay, Peter Barton, Sue Bickerton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2020
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs
Nicola Colclough, Kan Chen, Peter Johnström, et al.
Journal of Medicinal Chemistry
|
October 2, 2014
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor
M Raymond V Finlay, Mark Anderton, Susan Ashton, et al.
Page
of 70
Search research articles
Search
Showing results (681-690 of 694) with videos related to
Sort By:
Page
of 70
Journal of Medicinal Chemistry
|
August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)
Richard A Ward, Mark J Anderton, Susan Ashton, et al.
Cancer Research
|
March 21, 2020
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance <i>EGFR</i> Mutations
Jacqueline H Starrett, Alexis A Guernet, Maria Emanuela Cuomo, et al.
Genome Research
|
June 5, 2019
Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging
Aaron R Jeffries, Reza Maroofian, Claire G Salter, et al.
The Journal of Clinical Investigation
|
April 2, 2013
SLITRK6 mutations cause myopia and deafness in humans and mice
Mustafa Tekin, Barry A Chioza, Yoshifumi Matsumoto, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
September 8, 2022
Biallelic DAW1 variants cause a motile ciliopathy characterized by laterality defects and subtle ciliary beating abnormalities
Joseph S Leslie, Rim Hjeij, Asaf Vivante, et al.
Nature Communications
|
January 11, 2018
Guiding of relativistic electron beams in dense matter by laser-driven magnetostatic fields
M Bailly-Grandvaux, J J Santos, C Bellei, et al.
Cancer Discovery
|
June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Journal of Medicinal Chemistry
|
September 7, 2021
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
M Raymond V Finlay, Peter Barton, Sue Bickerton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2020
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs
Nicola Colclough, Kan Chen, Peter Johnström, et al.
Journal of Medicinal Chemistry
|
October 2, 2014
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor
M Raymond V Finlay, Mark Anderton, Susan Ashton, et al.
Page
of 70